Cost-effectiveness of sitagliptin-based treatment regimens in European patients with type 2 diabetes and haemoglobin A1c above target on metformin monotherapy

Diabetes, Obesity & Metabolism
B SchwarzH Sintonen

Abstract

Sitagliptin is a novel oral incretin enhancer that acts by inhibiting the dipeptidyl peptidase 4 enzyme and is indicated in Europe as a treatment adjunct to metformin (MF), sulphonylurea (SU), MF plus SU and diet and exercise, in the management of type 2 diabetes mellitus. The objective of the current analysis was to evaluate the cost-effectiveness of adding sitagliptin to the regimens of patients with haemoglobin A1c (HbA1C) above the International Diabetes Federation goal (6.5%) while on MF in six European countries: Austria, Finland, Portugal, Scotland (United Kingdom), Spain and Sweden. A discrete event simulation model, which employed the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model risk equations for predicting risks of diabetes-related complication, was used. Lifetime costs and benefits were projected for alternative treatment strategies of adding sitagliptin, compared with adding rosiglitazone or a SU to MF in patients not at HbA1C goal on MF monotherapy. Changes in HbA1C as well as side effects associated with these different treatment strategies were based on clinical trial data. Mean baseline values from local epidemiologic studies involving patients with type 2 diabetes not at HbA1C goal on MF mo...Continue Reading

References

May 22, 2002·JAMA : the Journal of the American Medical Association·UNKNOWN CDC Diabetes Cost-effectiveness Group
Jul 24, 2002·Diabetologia·B Jönsson, UNKNOWN CODE-2 Advisory Board
Nov 28, 2002·Diabetes Care·J Todd CoffeyWilliam H Herman
Dec 13, 2002·Journal of Diabetes and Its Complications·Richard J StevensUNKNOWN UK Prospective Diabetes Study (UKPDS58)
Jan 22, 2004·JAMA : the Journal of the American Medical Association·Sharon H SaydahCatherine C Cowie
Apr 15, 2004·European Journal of Public Health·Irmgard Schmitt-KoopmannThomas D Szucs
Jul 24, 2004·American Journal of Physiology. Endocrinology and Metabolism·Jens Juul Holst, Jesper Gromada
Nov 5, 2004·Current Opinion in Pharmacology·Jens Juul Holst, Carolyn F Deacon
Jan 29, 2005·Diabetes Care·Richard W GrantUNKNOWN University HealthSystem Consortium (UHC) Diabetes Benchmarking Project Team
Mar 12, 2005·The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care·Jonas LundkvistLinus Jönsson
Oct 18, 2005·The American Journal of Medicine·John E Gerich
Nov 7, 2006·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Evo AlemaoPekka Jousilahti
Sep 13, 2007·JAMA : the Journal of the American Medical Association·Sonal SinghCurt D Furberg
Jul 1, 2002·Diabetologia·B Jönsson

❮ Previous
Next ❯

Citations

May 9, 2012·Journal of Medical Economics·J Smith-PalmerW J Valentine
Aug 17, 2010·Expert Opinion on Drug Metabolism & Toxicology·André J Scheen
Jul 21, 2010·Current Medical Research and Opinion·Y YiK Burslem
Oct 18, 2011·Primary Care Diabetes·Ola GranströmMartin Henriksson
Mar 24, 2009·Clinical Therapeutics·Travis E SonnettStephen M Setter
Sep 3, 2011·Diabetic Medicine : a Journal of the British Diabetic Association·M J DaviesW J Valentine
May 29, 2016·The Lancet. Diabetes & Endocrinology·Kamlesh KhuntiMelanie J Davies
Jul 9, 2016·Health Economics Review·Varun VaidyaIftekhar Kalsekar
Oct 28, 2016·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Jason GordonJorge Puelles
Feb 8, 2019·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Stephané RozeMikko Honkasalo
Feb 27, 2010·Drugs & Aging·Silvia BustacchiniFabrizia Lattanzio
May 2, 2012·Journal of Oncology Practice·Scott R BerryChaim M Bell
Apr 30, 2013·Health Economics Review·Jorge F ElgartJuan J Gagliardino
Mar 5, 2015·PharmacoEconomics·Jinsong GengYingyao Chen
Oct 19, 2016·The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care·Alexandre BaptistaJulian Perelman

❮ Previous
Next ❯

Related Concepts

Related Feeds

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.